Drug Trial Radar · NCT04566328
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,450
Planned (sponsor's estimate)
Start
Feb 24, 2021
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- ECOG-ACRIN Cancer Research GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Sep 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Conditions
- Plasma Cell Myeloma
- RISS Stage I Plasma Cell Myeloma
- RISS Stage II Plasma Cell Myeloma
Interventions
BortezomibDrug
Given SC
Daratumumab and Hyaluronidase-fihjBiological
Given SC
DexamethasoneDrug
Given PO
LenalidomideDrug
Given PO
Quality-of-Life AssessmentOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Consolidation overall survivalTime frame: Time from Step 2 randomization at the start of consolidation to death or to the date last known alive, assessed up to 15 years
Locations
647 sites in 2 countries. Site status is shown where the registry gives one.
Anchorage Associates in Radiation Medicine
Anchorage, Alaska · Suspended
Anchorage Radiation Therapy Center
Anchorage, Alaska · Suspended
Alaska Breast Care and Surgery LLC
Anchorage, Alaska · Suspended
Alaska Oncology and Hematology LLC
Anchorage, Alaska · Suspended
Alaska Women's Cancer Care
Anchorage, Alaska · Suspended
Anchorage Oncology Centre
Anchorage, Alaska · Suspended
Katmai Oncology Group
Anchorage, Alaska · Suspended
Providence Alaska Medical Center
Anchorage, Alaska · Suspended
Cancer Center at Saint Joseph's
Phoenix, Arizona · Recruiting
University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona · Suspended
Banner University Medical Center - Tucson
Tucson, Arizona · Suspended
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Suspended
Mercy Hospital Fort Smith
Fort Smith, Arkansas · Recruiting
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas · Suspended
CARTI Cancer Center
Little Rock, Arkansas · Recruiting
John L McClellan Memorial Veterans Hospital
Little Rock, Arkansas · Suspended
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California · Recruiting
Sutter Auburn Faith Hospital
Auburn, California · Suspended
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California · Suspended
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California · Suspended
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California · Suspended
Mills-Peninsula Medical Center
Burlingame, California · Suspended
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California · Suspended
Mercy Cancer Center - Carmichael
Carmichael, California · Recruiting
Mercy San Juan Medical Center
Carmichael, California · Recruiting
Eden Hospital Medical Center
Castro Valley, California · Suspended
Sutter Davis Hospital
Davis, California · Suspended
Mercy Cancer Center - Elk Grove
Elk Grove, California · Recruiting
Palo Alto Medical Foundation-Fremont
Fremont, California · Suspended
Washington Health
Fremont, California · Recruiting
Mercy Cancer Center
Merced, California · Recruiting
Memorial Medical Center
Modesto, California · Suspended
Palo Alto Medical Foundation-Camino Division
Mountain View, California · Suspended
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California · Suspended
Sutter Cancer Research Consortium
Novato, California · Suspended
Palo Alto Medical Foundation Health Care
Palo Alto, California · Suspended
Mercy Cancer Center - Rocklin
Rocklin, California · Recruiting
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California · Suspended
Sutter Roseville Medical Center
Roseville, California · Suspended
Mercy Cancer Center - Sacramento
Sacramento, California · Recruiting
Showing 40 of 647 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.